QQ客服 官方微博 反馈留言

浏览/检索结果: 共5条，第1-5条 帮助 限定条件 发表日期：2013    专题：复旦大学上海医学院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial 期刊论文 LANCET ONCOLOGY, 2013, 卷号: 14, 期号: 10 作者:  Shi, Yuankai;  Zhang, Li;  Liu, Xiaoqing;  Zhou, Caicun;  Zhang, Li 收藏  |  浏览/下载：8/0  |  提交时间：2019/12/19 BIOMARKER ANALYSIS OF A RANDOMIZED, CONTROLLED, MULTICENTER CLINICAL TRIAL COMPARING PEMETREXED/CISPLATIN AND GMCITABINE/CISPLATIN AS FIRST-LINE TREATMENT FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER 会议论文 作者:  Zhang, Li;  Huang, Yan;  Hu, Zhihuang;  Liu, Yun-Peng;  Zhou, Jianying 收藏  |  浏览/下载：6/0  |  提交时间：2019/12/19 Lung cancer  chemotherapy  biomarker   BEYOND: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE, PHASE III STUDY OF FIRST-LINE CARBOPLATIN/PACLITAXEL (CP) PLUS BEVACIZUMAB (BV) OR PLACEBO (PL) IN CHINESE PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) 会议论文 作者:  Zhou, Caicun;  Chen, Gongyan;  Liu, Xiaoqing;  Zhu, Yunzhong;  Lu, Shun 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/19 NSCLC  Bevacizumab  Chinese patients  first line   FIRST-LINE ERLOTINIB VERSUS CISPLATIN/GEMCITABINE (GP) IN PATIENTS WITH ADVANCED EGFR MUTATION-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC): INTERIM ANALYSES FROM THE PHASE 3, OPEN-LABEL, ENSURE STUDY 会议论文 作者:  Wu, Yi-Long;  Liam, Chong-Kin;  Zhou, Caicun;  Wu, Gang;  Liu, Xiaoqing 收藏  |  浏览/下载：5/0  |  提交时间：2019/12/19 EGFR mutations  Asian patients  erlotinib  NSCLC   A Systematically Combined Genotype and Functional Combination Analysis of CYP2E1, CYP2D6, CYP2C9, CYP2C19 in Different Geographic Areas of Mainland China - A Basis for Personalized Therapy 期刊论文 PLOS ONE, 2013, 卷号: 8, 期号: 10 作者:  Wu, Zhenqiang;  Zhang, Xiaoqing;  Shen, Lu;  Xiong, Yuyu;  Wu, Xi 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/19